focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Learned to be invested in Shield on the hard way
I sold all my 1650000 shares for 1,25 on 30/3/24 with a big substiancial loss.
But now I´ve at least a perspective to reduce my losses.
I say goodbye to all long term investors, good luck !
For me Greg was the final straw with the Texas report. Unbelieveable!
Greg probably thinks Europeans are brain amputees that he can sell nonsense to anyone.
Nobody can suspend 3 months of prior authorizations for sometimes vital medications because a position is not occupied.
Here are information about Medicaid in Texas from the PBM, there are phone numbers on the last pages, feel free to ask about delays of Medicaid PA´s in Texas.
https://oig.hhs.texas.gov/sites/default/files/documents/reports/pbm-informational-report-final-9-30-2019.pdf
It was the first and last time I bought an AIM share.
Now I hope for better times with Nasdaq TGTX. The top product started one year later as Accrufer in the US but prescription growing, reaching the profit zone is total different to pound grave Shield.
Nice weekend to all but not for the BoD of Shield
Frank
Its online - webinar.
Nope, I do not attend shareholders meetings, too much travel and long days from Lincs.
Quote "Additionally, our stated initiatives to improve the average net selling price by increasing PA submission rates and more favorable Medicaid pricing following renegotiation of payer contracts, are progressing very well."
At this stage, they have successfully extended their financing and got improved terms on its existing $20 million debt financing with SWK Funding.
Let us know how it goes, still hoping for a blue day :)
Optrade, will you be attending today's investor meet ?
I will be for sure, want to see what their plans are to generate more revenue
Your Quote "The only thing going for you is that the value is low enough already that it might not crash further"
Yes, it's very undervalued, a good reason to BUY!
For your info, the results have been consistently strong and I don't see that there is anything in what you say will that stop it despite your built-up hate and dislike of the CEO.
Optrade last post from me as I don't want to upset you.
...But that couldn't be further from the truth. They did have sales momentum but it's totally lost. QoQ growth rate has dropped from 60% to 1% - that wouldn't be so bad if they were maturing at over 100k prescriptions per quarter but they are still only where they were meant to be last year before the full sales team had settled in.
The second key metric, net selling price, has also gone backwards this quarter too.
The only thing going for you is that the value is low enough already that it might not crash further, but there are now serious question marks around this management team and tbh, possibly even the product which is failing to gain traction.
GL, I hope this works out for you!
SMY, Shield is a small company with an experienced accountant who should control costs, their sales staff will be on high commissions. For what it's worth I don't care too much if they don't achieve the growth as fast as they want. They have a good product with a sales momentum that will be hard to stop so I believe they will continue to grow and be a profitable successful company.
I'm here for the long-term so it would be great it all the short-term negative posters move on without making things worse than what they are.
Optrade,
do you actually believe all the figures and the targets will be reached.?
They have been circa 50% of any target set previously so will it suddenly all change?
Good luck in your belief this will rocket today....lol
if it closes blue it will be fantastic
Q3 2023 - $8,500,000
Q4 2023 - $14,500,000
Q1 2024- $15,000,000
Q2 2024 -$16,500,000
Q3 2024 - $22,500,000
Q4 2024 - $31,500,000
Q1 2025 - $38,900,000
Looks ok to me :)
Q2 2025+
$45,700,000
HarChris: Like you, I see nothing in this update to justify the optimism shown by a couple of the other posters.
It is, however, consistent with how this operation rolls though.
Still very much on track to end up how I suggested this one is likely to.
Did I miss the part about what action they have taken against that third party, who they previously blamed for those false prescription numbers? Or has it all been forgiven and forgotten? Lol.
A zombie outfit, to all intents and purposes in my sincere opinion - but this is AIM, so who knows, the SP might have a spike.
This is a terrible update, not sure where the positives are. A 1% quarterly increase in prescriptions, based on a disappointing Q4 2023 too, is terrible. This needs to be growing c50% minimum. We were meant to be at 50k per quarter 6 months ago. Still miles off.
CEO is clearly clueless, and has an excuse for everything.
$10m of cash will clearly not last the year
Yes but they have got backers to handle it, which normal for a healthy growing company!
EV includes debt, Shield only have cash because they keep taking on more debt. The EV isn't increasing.
How can market cap be same as cash , basically no value is being given for EV .
Compare the sales to previous year, huge increase in sales . Yet the price is down here .
You might just be being naive but Shield is 'not doing a lot better than many other Aim companies' , at this stage revenue is irrelevant, they were on a path to profitability and now they are MILES away - they are burning cash like nobody's business and have a mcap of £10m to raise against vs a £100m mcap last year.
The debt facility gives them another quarter to show some significant improvement but if nothing seen them it must surely be curtains.
Very happy to see the comments about the debt facility. They will get there in the end I think
It may not be as fast but there is growth and Shield is doing a lot better than many other AIM companies with only a speculative higher SP which have yet to make any income.
SP is a bargain imo.
The real increase is 1% on Q4 2023 - for a company supposedly targeting 330k prescriptions in 2024 28.8k is a rubbish number and provides conclusive proof that growth is no longer on track.
This is going to rocket up today!